drugset / Trial / NCT05891613
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
Timeline
- Start
- 2024-01-24
- Primary completion
- 2025-10-06
- Completion
- 2025-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 50 mg | Subcutaneous |
| Subject | Bupivacaine | Other / unclassified | 266 mg | Other |
Indications
No indication recorded.